Indian Journal of Medical Research

: 2014  |  Volume : 140  |  Issue : 6  |  Page : 701--703

Long term impact of antiretroviral therapy - Can we end HIV epidemic, the goal beyond 2015

N Kumarasamy1, R Pendse2,  
1 YRGCARE Medical Centre, Voluntary Health Services, Chennai 600 113, Tamil Nadu, India
2 World Health Organization-SEARO, New Delhi 110 002, India

Correspondence Address:
N Kumarasamy
YRGCARE Medical Centre, Voluntary Health Services, Chennai 600 113, Tamil Nadu

How to cite this article:
Kumarasamy N, Pendse R. Long term impact of antiretroviral therapy - Can we end HIV epidemic, the goal beyond 2015.Indian J Med Res 2014;140:701-703

How to cite this URL:
Kumarasamy N, Pendse R. Long term impact of antiretroviral therapy - Can we end HIV epidemic, the goal beyond 2015. Indian J Med Res [serial online] 2014 [cited 2020 Apr 4 ];140:701-703
Available from:

Full Text

With the advent of antiretroviral therapy and with the production of generic antiretrovirals (ARVs) [1],[2] , 12.9 million persons with HIV disease are receiving antiretroviral treatment (ART) [3] . Dramatic decline in morbidity and mortality due to HIV disease has been observed both in the developed and developing countries [4],[5] . Robust scale-up of ART is happening in India [6] and in other lower and middle income countries (LMIC) [3] . Recent global update has clearly shown the declining death rate across the region among persons who were on ART [3] .

The HPTN052 study has shown 96 per cent reduction in sexual HIV transmission and reduction in incidence of tuberculosis following ART [7] . The WHO 2013 ARV guidelines [8] have recommended ART for all serodiscordant couples irrespective of CD4 cell count and for asymptomatics with CD4<500 cells/μl. This guidance will move the eligible numbers who need ART to 25 millions in LMIC. Recent global update has shown reduction in sexual transmission of HIV across the region [3] . When 2013 WHO ARV guidelines are implemented across the regions, greater impact on declining incidence are expected. The major obstacle is identifying individuals with CD4 >350 cells/μl. Data have shown the median CD4 to initiate ARV in low, lower middle and upper middle income countries is less than 200 cells/ml [9] . The mortality rate was higher in the first year after initiation of ART due to the low baseline CD4 cell count [10] .

Efforts should be made in each country on the frequency of HIV testing, which should be cultural specific and based on HIV incidence in different key populations. A recent modeling study done for India has shown that voluntary HIV screening among national population every five years and annual screening among high risk population and in high prevalent districts will offer substantial clinical benefit and be cost effective [11] . Similar exercise should be carried out in each country.

Tuberculosis continues to be the major co-factor in HIV disease progression in HIV infected persons [12] . The WHO has recommended isoniazid preventive therapy (IPT) which is being implemented and efforts should be done to make it universal in high endemic regions [8] . The WHO 2013 ARV guidelines recommend to initiate ART for all HIV/TB co-infected patients as soon as possible [8] . This will result in reduction in mortality among this population. The UNAIDS report has shown declining mortality in HIV/TB co-infected patients on ART between 2001-2012 [3] .

PEARLS/ACTG5175 study carried out in resource-limited settings has shown tenofovir (TDF) containing first line ART is safer and superior as compared to zidovudine (AZT) containing regimen [13] . Also modeling studies have shown tenofovir is cost-effective on a long run as compared to AZT [14] . Implementation of TDF containing first line fixed dose combination (FDC) ART should be given priority. Also creatinine monitoring should be implemented in ART programmes to identify early renal toxicities. Operational research is needed to identify the TDF related adverse effects for the inclusion in the future guidelines.

With the rapid scale-up of ARVs, need for 2 nd line ARVs is also on the rise. The absence of viral load monitoring can lead to immunological and clinical failure and also can jeopardize future regimens due to the accumulation of resistance mutations [15],[16],[17],[18] . Phasing in viral load technology in LMIC is an urgent priority and this needs resources and capacity building. Surveillance of ARV resistance should be carried out periodically in the national programmes to advise the future guidelines to incorporate newer class of first line ARV regimens [19],[20] .

Adherence to antiretroviral therapy and removing stigma are critical to get the maximum efficacy and the effectiveness of benefits. Local strategies to be developed and implemented to improve adherence. Family members, community and technologies like sending text messages through mobile phones should be used to improve medication adherence. Further, patient friendly care services, counselling and innovative techniques like phone reminders need to be implemented to avoid loss to follow up and to improve retention [21],[22] .

With the availability of simplified potent ART regimens, persons with HIV live longer. A cohort study conducted in India has shown a significant number of persons on ART living for more than 10 years [23] . The major reason for morbidity in this cohort was due to the non-AIDS complications like diabetes, cardiac, renal, and liver diseases, malignancy and neurocognitive impairement. A study from Brazil has also shown similar results [24] .

People living with HIV are now living longer due to the impact of expanded HIV treatment, but they are also facing non-HIV chronic conditions and experiencing high rates of morbidity related to non-communicable diseases (NCDs). With the increase in occurrence of non-communicable diseases in this population receiving long term ART, there is an urgent need to integrate HIV care in health service delivery.

Global progress in scale-up of ART has been extraordinary and a decrease in both morbidity and mortality is seen. Sustainability of ARV programmes will require forward looking policies, more effective and innovative approaches, together with further investments. Efforts should be in place to prevent the transmission of ARV resistant strains of HIV. Viral load monitoring and adherence counselling will assist this. With increasing NCDs in the HIV infected population, programmes should integrate HIV care in health service delivery to prevent and manage NCDs. The ARVs are a powerful tool towards ending the HIV epidemic. HIV might be positioned within the post-2015 development agenda, with a vision of 'ending the AIDS epidemic'.


1Kumarasamy N, Solomon S, Chaguturu SK, Mahajan AP, Flanigan TP, Balakrishnan P, et al. The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in South India. AIDS 2003; 7 : 2267-9.
2Kumarasamy N. Generic antiretroviral drugs-will they be the answer to HIV in the developing world? Lancet 2004; 364 : 3-4.
3Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338 : 853-60.
4Kumarasamy N, Solomon S, Chauguturu SK, Cecelia AJ, Vallabhaneni S, Flanigan TP, et al. The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in Southern India. Clin Infect Dis 2005; 41 : 1525-8.
5National AIDS Control Organisation, Facts and Figures. 2012. Available from:, accessed on October 15, 2014.
6UNAIDS report on the global AIDS epidemic 2013. Available from:, accessed on October 15, 2014.
7Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365 : 493-505.
8Consolidated Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: June 2013. Available from:, accessed on October 15, 2014.
9IeDEA and ART Cohort Collaborations, Avila D, Althoff KN, Mugglin C, Wools-Kaloustian K, Koller M, Dabis F, et al. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr 2014; 65 : e8-16.
10Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration; ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367 : 817-24.
11Venkatesh KK, Becker JE, Kumarasamy N, Nakamura YM, Mayer KH, Losina E, et al. Clinical impact and cost-effectiveness of expanded voluntary HIV testing in India. PLoS One 2013; 8 : e64604.
12Kumarasamy N, Solomon S, Flanigan T, Hemalatha R, Thyagarajan SP, Mayer KH. Natural history of human immunodeficiency virus disease in Southern India. Clin Infect Dis 2003; 36 : 79-85.
13Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, Firnhaber C, et al. PEARLS Study team of the ACTG. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational seetings. PLoS Med 2012; 9 : e 1001290.
14Bender MA, Kumarasamy N, Mayer KH, Wang B, Walensky RP, Flanigan T, et al, Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis 2010; 50 : 416-25.
15Kumarasamy N, Madhavan V, Venkatesh KK, Saravanan S, Kantor R, Balakrishnan P, et al. High frequency of clinically significant mutations after first-line generic high active antiretroviral therapy failure: Implications for second line options in resource-limited settings. Clin Infect Dis 2009; 49 : 306-9.
16Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44 : 447-52.
17DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006; 20 : 1391-9.
18Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23 : 1127-34.
19Phanuphak P, Sirivichayakul S, Jiamsakul A, Sungkanuparph S, Kumarasamy N, Lee MP, et al. Transmitted drug resistance and antiretroviral treatment outcomes in non-subtype B HIV-1-infected patients in South East Asia. J Acquir Immune Defic Syndr 2014; 66 : 74-9.
20Bertagnolio S, De Luca A, Vitoria M, Essajee S, Penazzato M, Hong SY, et al. Determinants of HIV drug resistance and public health implications in low- and middle-income countries. Antivir Ther 2012; 17 : 941-53.
21Kumarasamy N, Safren SA, Raminani SR, Pickard R, James R, Krishnan AK, et al. Barriers and facilitators to antiretroviral medication adherence among patients with HIV in Chennai, India: a qualitative study. AIDS Patient Care STDS 2005; 19 : 526-37.
22Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, Chung MH, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet 2010; 376 : 1838-45.
23Kumarasamy N. Long term impact of antiretroviral therapy in resource limited setting. In: Cell-The Lancet- A Translational Medicine conference on HIV research 2013; November 3-5. San Francisco, CA, USA. Available from:
24Grinsztejn B, Luz PM, Pacheco AG, Santos DV, Velasque L, Moreira RI, et al. Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era. PLoS One 2013; 8 : e59768.